Kaganovich: Most people derive no actionable information from genome sequencing
Mark Kaganovich · Mark Kaganovich, SolveBio // Data Infrastructure For Genomics // Data Driven NYC (FirstMark Capital) · Feb 18, 2015 · at 1:58
Mark Kaganovich, co-founder and CEO of SolveBio, addresses the current limitations of genome sequencing at Data Driven NYC.
0:00 / 0:03exact quote · 3.5s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“For most people, there's no information that they glean yet from it.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Mark Kaganovich
Kaganovich: Genetics companies build clinical DNA tests using unmanaged public FTPs
“Every genetics company, every hospital, they design and implement tests To figure out what disease you have, or don't have, or whether you should have a child, or what drug to take based on your DNA. They use this data that's collected by academics and deposit…”
Kaganovich: Human genome sequencing costs plummeted from $3 billion to $1,000
“This thing can sequence your genome for a thousand dollars, and it, 10 years ago, cost, like, three billion, and was really hard.”
Kaganovich: Public academic genomic databases lack quality control and version tracking
“It's great data for the first, kind of, chapter one of genetics, but the problem is that there's no quality control. You don't know what, which records are right, which records aren't relevant. There's no feedback for this worked for me, this didn't work for m…”
Kaganovich predicts multi-billion dollar companies will emerge around DNA variant measurement
“There will be multi-billion dollar companies that will figure out how to measure those efficiently, deliver that information to the patient, and get feedback from the patient.”
Kaganovich: Researchers distrust public genomic databases because submission standards vary wildly
“But no one trusts other people's submissions, we found, because the standards are different.”
Kaganovich: Genetics is undergoing a horizontalization phase similar to early microprocessors
“The way we kind of see it is that, that, that inflection point has already happened. It's somewhat akin to the microprocessor that forced a lot of horizontalization, de-aggregation of the industry. I think that's happening in genetics”